EZH2 and glioblastoma: In addition, glioblastoma cells were treated with a PRMT6 inhibitor (EPZ020411) for 48 h, and it was found that EZH2 protein expression in glioblastoma cells was significantly inhibited (Fig. 3C), suggesting that PRMT6 may regulate the expression level of EZH2 through post-translational modification.